ASP8825 |
HORIZANT |
GSK1838262 |
GABAPENTIN ENACARBIL |
XP-13512 |
XP 13512 |
GABAPENTIN ENCARBIL |
ASP-8825 |
GABAPENTINA ENACARBILO |
REGNITE® |
GABAPENTINE ENACARBIL |
GABAPENTINUM ENACARBILUM |
XP13512 |
HORIZANT® |
drugbank:08872 |
chemidplus:478296-72-9 |
rxcui:1101333 |
chembl:CHEMBL1628502 |
pubchem.compound:9883933 |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | for treatment of restless legs syndrome |
modulator |
Trial Name | XP13512 |
Novel drug target | Established target |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
Trial Name | XP13512 |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
Trial Name | XP13512 |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Drug Indications | for treatment of restless legs syndrome |
Drug Class | small molecule |
FDA Approval | not approved |